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Abstract
Background: A more stringent QuantiFERON-TB Gold In-Tube (QFT) conversion (from negative to positive)
definition has been proposed to allow more definite detection of recent tuberculosis (TB) infection. We explored
alternative conversion definitions to assist the interpretation of serial QFT results and estimate incidence of TB
infection in a large cohort study.
Methods: We used QFT serial results from TB household contacts aged ≥15 years, collected at baseline and during
two follow-up visits (2006–2011) as part of a cohort study in 24 communities in Zambia and South Africa (SA).
Conversion rates using the manufacturers’ definition (interferon-gamma (IFN-g) < 0.35 to ≥0.35, ‘def1’) were
compared with stricter definitions (IFN-g < 0.2 to ≥0.7 IU/ml, ‘def2’; IFN-g < 0.2 to ≥1.05 IU/ml, ‘def3’; IFN-g < 0.2 to
≥1.4 IU/ml, ‘def4’). Poisson regression was used for analysis.
Results: One thousand three hundred sixty-five individuals in Zambia and 822 in SA had QFT results available.
Among HIV-negative individuals, the QFT conversion rate was 27.4 per 100 person-years (CI:22.9–32.6) using def1,
19.0 using def2 (CI:15.2–23.7), 14.7 using def3 (CI:11.5–18.8), and 12.0 using def4 (CI:9.2–15.7). Relative differences
across def1-def4 were similar in Zambia and SA. Using def1, conversion was less likely if HIV positive not on
antiretroviral treatment compared to HIV negative (aRR = 0.7, 95%CI = 0.4–0.9), in analysis including both countries.
The same direction of associations were found using def 2–4.
Conclusion: High conversion rates were found even with the strictest definition, indicating high incidence of TB
infection among household contacts of TB patients in these communities. The trade-off between sensitivity and
specificity using different thresholds of QFT conversion remains unknown due to the absence of a reference
standard. However, we identified boundaries within which an appropriate definition might fall, and our strictest
definition plausibly has high specificity.
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Background
The impact of tuberculosis (TB) preventive treatment is
largely determined by adequate identification and diag-
nosis of individuals with an increased risk of progression
from latent TB infection (LTBI) to clinical disease. Both
the tuberculin skin test (TST) and two commercial
interferon gamma (IFN-g) release assays (IGRA),
QuantiFERON-TB Gold In-Tube (QFT) and T-
SPOT.TB assay, do not have a high accuracy for the pre-
diction of active TB and cannot differentiate between a
previously acquired and new TB infection [1, 2]. How-
ever, the IGRA offers a potential method of serial testing
to detect new TB infection and target high-risk individ-
uals for preventive treatment. Unlike the TST it can be
repeated without sensitization and boosting in subse-
quent tests, and it has better specificity than that of TST
in one-time screening [3, 4]. Several studies have indeed
shown that TB progression risk is higher among those
that recently converted, i.e., from a negative to a positive
IGRA result, compared to those who remained IGRA
negative on repeated testing [5, 6].
Since the Centers for Disease Control and Prevention
(CDC) has recommended QuantiFERON-TB Gold
(QFT) for baseline and serial testing [4], there is growing
evidence that IFN-g levels bordering the manufacturer’s
recommended assay cutoff of 0.35 IU/ml are more likely
to show discordant results upon serial testing [7–12].
These patterns are seen in settings with varying TB bur-
den, suggesting that at least some of the sources of
IGRA variability are immunological (i.e., boosting and
modulation) or due to assay reproducibility issues, inde-
pendent of the risk of exposure [11, 12]. Considering the
dynamic characteristics of IFN-g responses over time, a
simple dichotomous definition might not be appropriate.
Hence, several studies have suggested the introduction
of a ‘zone of uncertainty’ [5, 13–16] to assist in distin-
guishing new TB infections from non-specific variation.
It has been proposed that this zone should lie between
0.2 and 0.7 IU/ml to allow a more definitive detection of
recent TB infection and reduce the risk of unnecessary
initiation of preventive treatment in settings where
IGRA is used [17–20]. To date, only one large longitu-
dinal study, conducted by Nemes et al., has provided
sound evidence which supports the use of a stringent
QFT conversion definition using the proposed zone of
uncertainty [17]. More evidence is needed from larger
cohort studies and in other settings to inform guidelines
on serial QFT testing.
In this study we explored the use of the proposed zone
of uncertainty (between 0.2 and 0.7 IU/ml) and several
alternatives, to provide “boundaries” to assist in the in-
terpretation of serial QFT results and estimate incidence
of TB infection in a large cohort study. We use
epidemiological and clinical data collected among
household TB contacts during multiple years of follow-
up as part of a large community randomized trial, the
Zambia South Africa TB and AIDS Reduction (ZAM-
STAR) trial, carried out from 2005 to 2011 in 24 com-




The primary aim of the ZAMSTAR trial was to measure
the effect of household and community interventions on
TB prevalence and the incidence of new infection with
M. tuberculosis in the general population, described else-
where [21, 22]. Secondary outcomes in ZAMSTAR were
TB transmission within the households of TB patients,
and cumulative incidence of TB disease in household
contacts of TB patients [23]. We conducted a retrospect-
ive analysis using secondary outcome data collected
among the household members of newly diagnosed TB
cases. Households were recruited in each of the 24
ZAMSTAR communities. Study communities, urban,
peri-urban and rural, were selected based on TB notifi-
cation rates greater than 400/100,000 per annum and
having an HIV seroprevalence higher than estimated for
the whole country (Zambia) or province (Western Cape)
[21]. Findings from a 2010 HIV prevalence survey in
study communities estimated a seroprevalence of ap-
proximately 15% in Zambia and 20% in South Africa
[22].
Study population
Secondary outcomes at household level were measured
among a cohort of adult TB patients and their house-
hold members. After the start of the ZAMSTAR trial,
TB patients, subsequently referred to as index patients,
were recruited within 1 month of initiating TB treatment
at government TB diagnostic health facilities. The index
patient was asked for permission to visit his/her house-
hold, and if they gave permission then the household
was visited shortly afterwards and household members
(aged < 5 years and ≥ 15 years) were invited to partici-
pate. Household members were defined as individuals
who usually slept in the home, ate with the index patient
and who identified a common household head [23].
Data collection
The retrospective analysis in this study used epidemio-
logical and clinical data collected among the household
members who consented to participate, aged ≥15 years
and reported not to be on TB treatment at baseline (visit
1), subsequently referred to as household contacts.
Household contacts were visited from September 2006
to January 2011 and QFT tests were conducted from
January 2007. Hence, a large proportion of recruited
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contacts did not have a QFT result available at visit 1
(Fig. 1). Data were collected at visit 1 (January 2007–Au-
gust 2008), and during two follow-up measurements:
visit 2 (September 2008–February 2010) and visit 3 (July
2010–January 2011). Median follow-up time was 16
months (range 11–21) between visit 1-visit 2, and 18
months (range 15–20) between visit 2-visit 3.
Household contacts were asked to respond to a struc-
tured questionnaire during household visit 1. Data on
sex, age, marital status, education level, employment sta-
tus, smoking history, alcohol use, drug use, and experi-
ence of TB and HIV treatment were collected. Data
from TB index patients (sex, age and HIV status) were
linked to contact data through a common household
number if written informed consent was obtained. Add-
itional clinical index characteristics were obtained if the
index patient could be linked to the national TB register,
and included type of TB (pulmonary, extrapulmonary,
and smear status), and index patient type (transferred,
relapsed, new, resumed). Remaining data collected for
each household included: household wealth status (based
on an asset index), baseline TST prevalence region, and
whether the household was part of the ZAMSTAR
household intervention. The covariate baseline TST
prevalence region, a marker of TB infection prevalence
in the general community, was established from TST
prevalence surveys conducted among primary school
children in all 24 communities at the start of the ZAM-
STAR trial [22, 24]. These surveys were used to
characterize ZAMSTAR communities, regarding baseline
TST prevalence. The covariate household intervention
(yes or no) represents the outcome of the randomisation
of ZAMSTAR communities into intervention arms. Two
trial interventions were delivered between 2006 and
2009 and included community-based enhanced case
finding for tuberculosis (ECF intervention) and house-
hold counselling and provision of combined TB/HIV
prevention services at the household level (HH interven-
tion). The interventions were randomised in a factorial
design so that 6 communities received standard-of-care,
6 ECF alone, 6 HH counselling alone, and 6 both ECF
and HH interventions [21].
During each visit (visit 1, visit 2, visit 3), a venous
blood sample was collected for laboratory HIV testing
and QFT testing among household contacts who con-
sented to participate and also to provide a blood sample.
TSTs were also performed, independent of positivity
during previous visits. HIV testing was done using the
Fig. 1 Flow chart household contacts eligible for analysis
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Abbot Murex HIV Ag/Ab combination ELISA (Murex
Biotech, Dartford, United Kingdom). TB infection was
measured by TST and QFT at baseline and during
follow-up. The TST was conducted using 2 TU (Tuber-
culin Units) of purified protein derivative RT23 with
Tween, supplied by the Statens Serum Institut
(Copenhagen, Denmark). A dose of 0.1 ml was injected
intradermally on the left forearm. Skin reactions were
read using calipers 72 h later. TST and QFT tests were
performed according to the manufacturer’s instructions.
Blood for QFT was drawn before TST was administered
usually on the same day.
Study outcomes
Our main outcomes were QFT positivity at visit 1 and
QFT conversion at visit 2/3. Published literature and the
distribution of IFN-g values in our study were investi-
gated to define definitions of QFT positivity and QFT
conversion with different IFN-g assay cutoffs. QFT re-
sults in our data were expressed as IFN-g concentration
IU/ml. This was calculated as TB antigen (TBAg) re-
sponse minus the assays’ negative control response (Nil).
QFT cannot accurately measure absolute IFN-g values
greater than 10 IU/ml, therefore such values were treated
as 10 IU/ml. Indeterminate outcomes were excluded
from the analyses.
Baseline QFT positivity
Previous studies questioned the use of the manufacturers
cut-off for a positive QFT result (IFN-g ≥ 0.35) and have
proposed using a ‘zone of uncertainty’ between 0.2 and
0.7 IU/ml. We explored the use of this zone by plotting
histograms to visualize the distribution of IFN-g IU/ml
at visit 1. Histograms were plotted among HIV negative
household contacts as immunosuppression by HIV in-
fection can result in a diminished antigen response,
resulting in a low negative predictive value of the IGRA
in HIV positive individuals [25].
QFT conversion
Incidence rates of QFT conversion (from a negative
QFT result at visit 1 to a positive QFT result at either
visit 2 or visit 3) were calculated using the QFT conver-
sion definition as suggested by previous studies (IFN-g <
0.2, ≥0.7 IU/ml). These rates were compared with inci-
dence rates using stricter QFT conversion definitions.
Histograms were plotted of the absolute IFN-g distribu-
tion at visit 2 among contacts with a negative QFT at
visit 1, and of the distribution of change in IFN-g be-
tween visit 1 and visit 2 to help to determine stricter
conversion definitions. All histograms were plotted




TB household contacts were eligible for baseline analysis
if they had a visit 1 QFT result available and if they self-
reported not on TB treatment. The prevalence of infec-
tion was defined as the number of QFT positive results
among the total number of individuals with a positive or
negative result. The strength of the relationship between
individual and household characteristics and QFT
positivity was assessed with random effects logistic re-
gression. The random effects approach specified the
household of residence as the clustering variable in uni-
variable and multivariable analysis. Two different multi-
variable models were developed. The first multivariable
model included a priori selected contact- and household
characteristics: sex, age, HIV status, household interven-
tion (Y/N) and TST prevalence region. In this model all
factors were added simultaneously. The second multivar-
iable model was built using forward selection and
assessed the relationship between all available contact-,
index-, and household characteristics with the outcome,
guided by the strength of evidence for the association
with the outcome. First, factors significantly associated
with QFT positivity (overall p-value< 0.05) in univariable
analysis were simultaneously added to the a priori model
(including sex, age, HIV status, and TST prevalence re-
gion). Second, only factors that showed evidence of asso-
ciation after adjustment for a priori factors were
included in the subsequent model building step. In this
step factors were added one by one to assess the associ-
ation between each characteristic and outcome using the
Wald test. Only factors that showed evidence of associ-
ation were included in the final multivariable model. Un-
adjusted and adjusted odds ratios (ORs) and 95%
confidence intervals (CIs) were presented for each risk
factor. Analysis was performed for both countries com-
bined, and separately for Zambia and South Africa.
Conversion analysis
Contacts were eligible for QFT conversion analysis if
their QFT result was negative at visit 1 and if they had a
positive or negative result available at visit 2 and/or visit
3. Contacts were excluded from analysis if they had a
missing QFT result at both visit 2 and visit 3. Incidence
rates (IRs) and 95% CIs were reported as number of con-
version events per 100 person-years of follow-up time.
The date of visit 1 was used as the start of follow-up of
the household contact. Follow-up time ended halfway
between visit 1 and 2 if conversion occurred at visit 2, or
halfway between visit 2 and visit 3 if QFT was negative
at visit 2 and conversion occurred at visit 3. End follow-
up time of contacts who did not convert was placed at
the date of the last available negative QFT test result.
Visit 2 dates were imputed for those with missing QFT
Sloot et al. BMC Infectious Diseases          (2020) 20:760 Page 4 of 19
values at visit 2 and a valid value at visit 3. Dates were
imputed as the median date of available visit 2 dates,
stratified by community (24 communities). Analysis time
was split into two time-bands (visit 1- visit 2 and visit 2-
visit 3) to compare QFT conversion rates between visit
1–2 and visit 2–3. Additionally, IRs of the analysis that
included all contact outcomes were compared to the IRs
of the analysis restricted to contacts who had QFT
known at visit 2.
The strength of the relationship between individual
and household characteristics and QFT conversion was
assessed using Poisson regression analysis in a similar
way as described for baseline logistic regression analysis
(with an a priori model, and forward selection). Un-
adjusted and adjusted rate ratios (RRs) and 95%CIs were
presented for each risk factor in the a priori model. Risk
factors in the forward selection model were only pre-
sented if associated with the outcome. Analyses were
done for both countries combined, and separately for
Zambia and South Africa. All analyses were completed
in Stata (version 14.0; Stata Corp, College Station, TX).
Results
Study population
Nine thousand four hundred sixty-seven household
members aged ≥15 years gave consent to participate at
visit 1 in the year 2007 (Fig. 1). Among these were 4808
(51%) household contacts not on TB treatment. Contacts
with a QFT result available at visit 1 were eligible for
analysis (2187/4808, 46%). These contacts did not differ
(sex, age, HIV status) from the 2621 contacts that did
not have a QFT result available at visit 1 (Fig. 1). Among
household contacts eligible for analysis, 1365 (62%) con-
tacts were recruited from 805 households in Zambia,
and 822 (38%) contacts were recruited from 474 house-
holds in South Africa.
Of the 1365 household contacts in Zambia, 1164 had a
valid (positive or negative) QFT test result and 201 were
indeterminate (using manufacturers’ definition, Table 1).
In South Africa, 804 contacts had a valid (positive or nega-
tive) QFT test result and 18 were indeterminate (using
manufacturers’ definition, Table 1). In both Zambia and
South Africa the majority were female, aged between 15
and 24 years and were HIV negative (Table A1, additional
file). One thousand two hundred twenty-two of 1968 con-
tacts had TB status available at one or both follow-up
visits. In total, 57 (5%) of the 1222 contacts developed TB
during follow-up, with only a minority (17/57, 30%) diag-
nosed after visit 2, so we did not use TB incidence out-
comes to inform conversion definitions. Median time
between TB diagnosis and the most recently available
prior QFT test result was 9months (IQR = 4–15). Fig. A1
(additional file) shows the distribution of these IFN-g re-
sults (prior to TB diagnosis) among 57 household contacts
who developed TB during follow-up, and Fig. A2 (add-
itional file) shows the IFN-g distribution among 1165 con-
tacts who did not develop TB. Contacts who developed
TB had a higher median IFN-g response prior to diagno-
sis, were older, and a higher proportion were HIV-
positive, compared with the contacts who did not develop
TB (Table A2, additional file).
Determining QFT test cut-offs
Quantitative IFN-g values of the QFT results at visit 1
were plotted in histograms (Fig. 2) and showed the ab-
sence of any natural quantitative breakpoint in both
countries (Fig. 2b and d). Therefore, stricter definitions
to the manufacturer’s definition of QFT positivity (IFN-
g ≥ 0.35 IU/ml) were based on a conventional approach;
we chose multiples of 2, 3, and 4 times the manufac-
turer’s definition and used 0.7, 1.05, and 1.4 as cut-offs
to define positive versus negative responses.
TB infection prevalence in our cohort was described
using a stricter definition (IFN-g ≥ 0.7 IU/ml) and a less
strict definition (IFN-g ≥ 0.2 IU/ml) of baseline QFT posi-
tivity, to provide “boundaries” to our estimates (Table 1).
Plotting the quantitative values of the QFT results at visit
2 among contacts with a negative QFT result (< 0.35 IU/
ml) at visit 1 (Fig. 3) show that the majority of contacts
negative at visit 1 remained negative (< 0.35) at visit 2, in
both Zambia (124/172, 72%) and South Africa (40/63,
63%). The remaining IFN-g values did not show a clear
“breakpoint” between 0.35–1.4 IU/ml (Fig. 3).
Based on literature, and findings in Fig. 3, we explored
the following alternatives to the manufacturer’s conver-
sion definition (< 0.35, ≥0.35 IU/ml, definition 1): a nega-
tive result at visit 1 was defined as < 0.2 IU/ml and
conversion during follow-up as either ≥0.7 (definition 2),
≥1.05 (definition 3), or ≥ 1.4 (definition 4) IU/ml (Table 2).
Figure 4 shows the distribution of change in IFN-g be-
tween visit 1 and visit 2 among HIV negative household
contacts. 120/721 contacts (17%), who had a valid test
result available at visit 1 and visit 2, had the same IFN-g
value at both timepoints, 265 (37%) had a decrease in
IFN-g, 99 (14%) had an IFN-g increase between 0 and
0.5 IU/ml, and 237 (33%) had an increase of IFN-g ≥ 0.5
IU/ml. Figure 4b shows that among 45 contacts who
converted according to conversion definition 2 (IFN-g
visit 1 < 0.2, visit 2 ≥ 0.7 IU/ml), 25 (56%) contacts had
an IFN-g increase between 0.5–2.5 IU/ml, and the
remaining 20 contacts had an increase ≥2.5 (44%). Figure
4c shows the distribution for 37 contacts who converted
using definition 3 (IFN-g visit 1 < 0.2, visit 2 ≥ 1.05 IU/
ml). 17 (46%) contacts had an IFN-g increase between
0.5–2.5 IU/ml, and the remaining 20 (54%) contacts had
an increase ≥2.5. Corresponding figures among 28 con-
tacts who converted using definition 4 (IFN-g visit 1 <
0.2, visit 2 ≥ 1.4 IU/ml) show: 8 (29%) had an increase











































































































































































































































































































































































































































































































































































































































































































Fig. 2 Distribution visit 1 IFN-gamma results among HIV negative household contacts with a valid IFN-gamma value. a. Zambia, all results (n =
797); b. Zambia, zoomed-in (0–1 IU/ml); c. South Africa, all results (n = 605); d. South Africa, zoomed-in (0–1 IU/ml). Baseline definition 2 (Table 1)
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Fig. 3 Distribution IFN-gamma results at visit 2 among HIV negative household contacts with a negative QFT result at visit 1. a. Zambia, all results
(n = 172); b. South Africa, all results (n = 63). Baseline definition 2 (Table 1) was used to select contacts with a negative QFT result (< 0.35 IU/ml) at
visit 1. No rules were applied to visit 2; all valid (positive and negative) IFN-g values were included
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between 0.5–2.5 IU/ml, and 20 (71%) an increase ≥2.5
(Fig. 4d).
Baseline results
The proportion of household contacts who tested
QFT positive at visit 1 using the three different defi-
nitions was higher in South Africa than in Zambia
among HIV negative contacts (67–82% and 55–65%,
respectively) (Table 3). In the analysis including both
countries, the association between HIV status and
QFT positivity was similar across definition 1–3. Con-
tacts were less likely to be QFT positive if HIV posi-
tive; either if not on ARV (aOR:0.5, 95%CI:0.4–0.6)
using definition 1–3, or if on ARV (aOR:0.4, 95%CI:
0.2–0.8) using definition 1 and 3, and (aOR:0.4,
95%CI:0.3–0.8) using definition 2. The same direction
of association for HIV status was found in both
Zambia and South Africa, although evidence of asso-
ciation was weaker among HIV-positive individuals on
ARV in South Africa, but numbers were small (Table
3). The proportion of household contacts who tested
QFT positive at visit 1 was higher in communities
with higher TST prevalence, visible across definitions
and in both countries. Estimates of all variables in
unadjusted analysis using definition 2 (Table A1, add-
itional file) did not differ much from estimates in ad-
justed analysis (Table 3).
Table A3 (additional file) presents index factors associ-
ated with QFT positivity (using definition 2). Household
contacts were less likely QFT positive at visit 1 if the
index patient had extra pulmonary TB (EPTB) compared
to contacts with a pulmonary TB (PTB) smear positive
index (aOR:0.6, 95%CI:0.4–0.9 including both countries,
and aOR:0.5, 95%CI:0.3–0.8 for Zambia only). In
Zambia, contacts were also less likely QFT positive if the
index patient was PTB smear negative compared to hav-
ing a PTB smear positive index (aOR:0.7, 95%CI:0.5–0.9)
(Table A3). No association between index patient smear
status or other index characteristics and QFT positivity









































































Fig. 4 Distribution of change in IFN-gamma between visit 1 and visit 2 among HIV negative household contacts. a-d is shown for contacts (from
both Zambia and South Africa) if they: a. had a valid QFT result available at visit 1 and visit 2; b. converted (< 0.2, ≥0.7); c. converted (< 0.2,
≥1.05); d. converted (< 0.2, ≥1.4). Baseline definition 2 (Table 1) was used to identify contacts with a valid (positive or negative) IFN-gamma value
at visit 1 and 2
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Conversion results
Table A4 (additional file) shows the conversion analysis
for the study population and how conversion status and
follow-up time were calculated among household con-
tacts with a negative QFT result at visit 1 using conver-
sion definition 2. Identical principles were applied for
the other three conversion definitions.
Conversion rates were similar between visit 1 and 2 com-
pared to visit 2 and 3 in the analysis including both coun-
tries and in Zambia, and were lower between visit 2 and 3
compared to visit 1 and 2 in South Africa (Table 4). Among
HIV-negative individuals, in the analysis including both
countries, the QFT conversion rate was 27.4 per 100
person-years (95%CI:22.9–32.6) using definition 1, 19.0
using definition 2 (95%CI:15.2–23.7), 14.7 using definition
3 (95%CI:11.5–18.8), and 12.0 using definition 4 (95%CI:
9.2–15.7). IRs were higher in Zambia than in South Africa.
IRs were lower among HIV positive contacts not on ARV
in the analysis including both countries: 15.8 (95%CI:11.7–
21.4) definition 1, 12.3 (95%CI:8.6–17.6) definition 2, 9.7
(95%CI:6.5–14.4) definition 3, and 8.8 (95%CI:5.8–13.3)
definition 4. Table 4 further shows that, irrespective of
which conversion definition was used, similar HIV status
patterns were observed in Zambia: HIV negative contacts
had higher conversion rates compared to HIV positive con-
tacts not on ARVs. In South Africa definition 2–4 showed
different patterns (HIV positives not on ARV had higher
IRs than HIV negatives), however numbers are small, and
CIs wide. Conversion rates were higher in communities
with higher levels of TST prevalence, visible in both coun-
tries. A sensitivity analysis was done restricted to contacts
who had visit 2 QFT result known (Table A5, additional
file) and showed comparable incidence rates to Table 4.
The analysis including both countries using definition 1,
showed that females were less likely than males to convert
during follow-up (aRR = 0.7, 95%CI = 0.5–0.9), as were
HIV positive contacts not on ARV compared to HIV
negative contacts (aRR = 0.7, 95%CI = 0.4–0.9) (Table 5).
A similar pattern for sex and HIV status was observed
among stricter definitions but evidence of association was
weaker. Contacts living in an urban, low TST prevalence
area in Zambia were less likely to convert than contacts
living in Lusaka, a high TST area (aRR = 0.4, 95%CI = 0.3–
0.7, definition 1). This pattern remained statistically sig-
nificant for stricter conversion definitions. A similar trend
was visible in South Africa, but numbers are small (Table
5). Analysis using all available contact-, index-, and house-
hold characteristics did not reveal any additional associa-
tions between characteristics and QFT conversion (results
not shown).
Discussion
IGRA converters have a higher risk of subsequently de-
veloping active TB than those who remain negative on
repeated testing [6, 17]. However, previous studies have
suggested that the conversion definition should be stric-
ter than the current manufacturers’ definition, to enable
more accurate identification of recent TB infection [17–
20]. In this paper we assessed the distribution of IFN-g
values, using serial QFT results collected among house-
hold TB contacts, to guide identification of stricter con-
version definitions, which were then used to assist the
interpretation of QFT conversion results and to estimate
the incidence of TB infection. We found that QFT con-
version rates were relatively high, even using a more
stringent definition than the manufacturer’s definition,
indicating high incidence of TB infection among house-
hold TB contacts in these communities.
Our study identified three stricter conversion definitions
to estimate the incidence of TB infection. Each conversion
definition included a mandatory absolute increase between
baseline and follow-up QFT measurements, varying from
0.5 to 1.2 IU/ml. We found that sex of contact, HIV status
and TST prevalence region, all well established risk factors
of TB infection risk, were associated with QFT conversion.
With stricter conversion definitions, associations between
aforementioned risk factors and conversion continued to
show similar patterns. Our strictest definition plausibly has
high specificity. However, the trade-off between sensitivity
and specificity using different thresholds of QFT conver-
sion remains unknown, due to the absence of a reference
standard, and because we could not identify clear “break-
points” in the distribution of IFN-g response.
Irrespective of which conversion definition was used,
incidence of TB infection estimates were high, at 14.4–
30.7 per 100 person years in Zambia and 6.7–20.8 in
South Africa, measured among HIV negative TB con-
tacts. These rates were much higher than found in previ-
ous studies in South Africa estimating the annual risk of
tuberculosis infection (ARTI) [24, 26–28]. The ARTI is
considered the best epidemiological indicator to measure
the extent of TB transmission at community level [29].
Previous TST surveys conducted among children in high
TB incidence communities in South Africa found an
ARTI of 4% [24, 26, 27]. Dodd et al. modelled TB infec-
tion incidence among adults based on data from a social
contact pattern survey and TST prevalence survey, con-
ducted in the same South African and Zambian commu-
nities as our study [28]. The ARTI was estimated at 6–
8% for females and 7–10% for males in South Africa and
2–5% for females and 3–7% for males in Zambia.
The relatively higher incidence estimates found in our
study suggest that, despite high background rates of infec-
tion in the general community, the risk of acquiring infec-
tion with M. tuberculosis is still higher among household
members of TB patients. Consistent with our findings, Ver-
ver et al. showed that household contacts of TB patients
still have a higher risk of being infected with the same M.
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tuberculosis strain as the index patient than do community
contacts in South Africa [30]. Thus, while previous evi-
dence has suggested a substantial role for transmission
outside the household [31–33], it remains important to
consider household transmission when designing interven-
tions to reduce the incidence of new infection and to re-
duce the risk of infection progressing to disease.
TB infection prevalence estimates in our study, mea-
sured by QFT positivity at baseline, were higher in South
Africa than in Zambia (67–82% and 55–65%, respectively
among HIV negative contacts). The 2005 TST prevalence
survey, conducted at baseline of the ZAMSTAR trial, also
reported higher TB infection prevalence in South Africa
compared to Zambia [22]. Indeed, South Africa is still
among the countries with the highest TB incidence in the
world [34], and the communities involved in this study
were high-density residential areas [22]. In contrast to the
infection prevalence at baseline, the incidence rates among
household contacts of TB patients in our study were
higher in Zambia compared with South Africa. This might
be the result of a local saturation of susceptible individ-
uals. Infected individuals are generally linked to other in-
fected individuals, by whom they were infected or to
whom they have transmitted infection [35]. As a result,
the number of contacts between infected and susceptible
individuals is reduced over time and the spread of infec-
tion slowed. This might explain the greater proportion
with TB infection at baseline compared to the smaller pro-
portion with new infections during follow-up in South Af-
rican households, and the other way around in Zambian
TB households. It might also reflect different living condi-
tions in the Zambian and South African communities,
and/or differences among the TB index patients in the
time from developing TB disease to being diagnosed with
TB and starting TB treatment.
TB infection prevalence and incidence were consider-
ably lower among HIV positive contacts on ARV com-
pared to HIV negative contacts. This is probably the
result of immunosuppression by HIV infection on the
antigen response which can result in a low negative pre-
dictive value of the IGRA in HIV positive individuals
[25]. Accurate identification of TB infection among im-
munocompromised patients significantly diminishes the
risk of developing active TB if they are put on preventive
treatment, so more accurate diagnostic tests for TB in-
fection would be valuable. The recently FDA-cleared
QuantiFERON-TB Gold Plus has been proposed to im-
prove the detection of TB infection in immunocom-
promised patients through stimulation of CD8+ T cells
[36–38]. However, initial studies show high overall
agreement with the QFT-GIT, suggesting a minimal dif-
ference in assay performance [37, 39, 40].
This study had several limitations. First, incidence of TB
infection estimates in this study of household contacts
were based on QFT outcomes, and they were compared
to ARTI estimates for the general population that were
made from community TST surveys. We cannot exclude
the possibility that differences in estimates found in our
study are partly the result of different tests used, and it
has previously been shown that there was considerable
discordance between the QFT and TST response at base-
line in the same communities as our study [41]. Second,
we might have overestimated the amount of transmission
attributable to household transmission. We found that
conversion rates were fairly similar between visit 2 and 3
compared to visit 1 and 2. Whether this persistent risk re-
flects household transmission, ongoing community trans-
mission, clustering of risk factors within TB-affected
households, reactivation of latent TB infection, or a com-
bination of factors, our findings emphasise the need for in-
creased case detection in these study communities.
Further research is required to determine whether active-,
passive- or community-wide TB case finding is most ef-
fective in reducing the prevalence of TB in these commu-
nities. Future studies assessing QFT conversion should
aim to follow individuals up for at least several years, to
allow TB progression after conversion. Also, if M. tubercu-
losis genotyping was done for both the index patient and a
household contact who subsequently developed TB, this
would help to distinguish within-household versus com-
munity transmission and enable more accurate estimates
of household transmission. Finally, since we only started
testing with QFT half way through recruitment of house-
hold contacts we had to exclude a substantial proportion
of eligible contacts from our study. However, we do not
expect that this resulted in bias since the timing of when
households were enrolled depended only on when an
index TB patient was diagnosed at the clinic.
Conclusions
This study found high QFT conversion rates even with
the strictest conversion definition, indicating high inci-
dence of TB infection among household contacts of TB
patients in South African and Zambian communities. The
boundaries of more to less strict definitions of QFT con-
version provided in this study can assist the interpretation
of serial QFT outcomes and to estimate TB infection inci-
dence in comparable settings. These findings add to the
limited evidence on the performance of serial IGRA test-
ing in large longitudinal studies. Future studies should
evaluate the proposed stringent conversion definitions in
different settings and populations to determine its applica-
tion to target individuals for preventive TB treatment.
Until then, serial IGRA results should be interpreted with
caution. Individuals who convert according to the manu-
facturers’ definition should be closely monitored to con-
firm conversion at a later time, especially low-risk
individuals.
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Additional file 1 Fig. A1. Distribution IFN-gamma results among 57
household contacts who developed tuberculosis during follow-up. * The
most recently available QFT test result prior to TB diagnosis was used. For
n = 40 contacts who developed TB between V1-V2, this was QFT test re-
sult at visit 1. For n = 17 contacts who developed TB between V2-V3, this
was QFT test result at visit 2 (n = 12), or at visit 1 when visit 2 QFT test re-
sult was missing (n = 5). ** Histogram was plotted among both HIV nega-
tive and HIV positive household contacts.
Additional file 2 Fig. A2. Distribution IFN-gamma results among 1165
household contacts who did not develop tuberculosis during follow-up. *
QFT test result at visit 1 was used for the 1165 contacts who did not de-
velop TB during follow-up. ** Histogram was plotted among both HIV
negative and HIV positive household contacts
Additional file 3 Table A1. Factors associated with a positive QFT
result at visit 1 using definition 2 (≥0.35 IU/ml). * sex, age, HIV status, HH
intervention (yes/no), and region by TST prevalence were simultaneously
added to the regression models ** Unknown HIV status not shown
Additional file 4 Table A2. Characteristics of household contacts by
incident tuberculosis status. 1 Pearson’s chi-squared test, unless stated
otherwise. 2 Two-sample Wilcoxon rank-sum (Mann-Whitney) test. * The
most recently available QFT test result prior to TB diagnosis was used. For
n = 40 contacts who developed TB between V1-V2, this was QFT test re-
sult at visit 1. For n = 17 contacts who developed TB between V2-V3, this
was QFT test result at visit 2 (n = 12), or at visit 1 when visit 2 QFT test re-
sult was missing (n = 5). ** QFT test result at visit 1 was used for the 1165
contacts who did not develop TB during follow-up.
Additional file 5 Table A3. Index patient characteristics associated with
a positive QFT result at visit 1 using definition 2 (≥0.35 IU/ml).
*Regression models were constructed using forward selection as
described in Methods, using all available contact-, index-, and household
characteristics. Only index factors associated with outcome were
presented.
Additional file 6 Table A4 Study population QFT conversion analysis
using conversion definition 2 (< 0.2, ≥0.7). a End point follow-up was
placed halfway visits for contacts who converted, and was the date of
the last negative QFT measurement for contacts who did not convert. To
account for uncertainty between the follow-up QFT measurements, ana-
lysis time was split into visit 1-visit 2 and visit 2-visit 3. b A random vari-
able allocated approximately 50% of contacts with unknown visit 2 status
and conversion at visit 3, to have end point follow-up halfway visit 1-visit
2 and ~ 50% half-way visit 2-visit 3. This was informed by the distribution
of QFT conversion between visit 1–2 and visit 2–3 among contacts with
an available QFT measurement at visit 1, 2, and 3.
Additional file 7 Table A5. Incidence rate QFT conversion at visit 2 and
visit 3 using different definitions of conversion. This analysis is restricted to
household contacts who have a known visit 2 QFT result.
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